DE60232733D1 - Alternativ gesplicter zirkulierender gewebefaktor - Google Patents

Alternativ gesplicter zirkulierender gewebefaktor

Info

Publication number
DE60232733D1
DE60232733D1 DE60232733T DE60232733T DE60232733D1 DE 60232733 D1 DE60232733 D1 DE 60232733D1 DE 60232733 T DE60232733 T DE 60232733T DE 60232733 T DE60232733 T DE 60232733T DE 60232733 D1 DE60232733 D1 DE 60232733D1
Authority
DE
Germany
Prior art keywords
alt
htf
tissue factor
elevated
human tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60232733T
Other languages
English (en)
Inventor
Yale Nemerson
Vladimir Bogdanov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icahn School of Medicine at Mount Sinai
Original Assignee
Mount Sinai School of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mount Sinai School of Medicine filed Critical Mount Sinai School of Medicine
Application granted granted Critical
Publication of DE60232733D1 publication Critical patent/DE60232733D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • External Artificial Organs (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60232733T 2001-08-30 2002-08-29 Alternativ gesplicter zirkulierender gewebefaktor Expired - Lifetime DE60232733D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31624401P 2001-08-30 2001-08-30
PCT/US2002/027533 WO2003020111A2 (en) 2001-08-30 2002-08-29 Alternatively spliced circulating tissue factor

Publications (1)

Publication Number Publication Date
DE60232733D1 true DE60232733D1 (de) 2009-08-06

Family

ID=23228197

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60232733T Expired - Lifetime DE60232733D1 (de) 2001-08-30 2002-08-29 Alternativ gesplicter zirkulierender gewebefaktor

Country Status (6)

Country Link
US (1) US7045350B2 (de)
EP (1) EP1429650B1 (de)
AT (1) ATE434404T1 (de)
AU (1) AU2002361471A1 (de)
DE (1) DE60232733D1 (de)
WO (1) WO2003020111A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1554381T3 (da) * 2002-02-07 2010-03-29 Sirnasense As Posttranskriptionel silencing af vævsfaktorekspression med korte interfererende RNA'er
US7425328B2 (en) * 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
WO2008054822A2 (en) * 2006-11-03 2008-05-08 Angiogen Llc Compositions comprising alternatively spliced tissue factor (as tf) and methods for use
US20100297621A1 (en) * 2007-06-20 2010-11-25 University Of Utah Research Foundation Use of pre-mrna splicing in platelet cells for the diagnosis of disease
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
WO2011144953A1 (en) * 2010-05-18 2011-11-24 Diagon Kft. Procedure for producing recombinant human tissue factor
US9168314B2 (en) 2010-06-15 2015-10-27 Genmab A/S Human antibody drug conjugates against tissue factor
US9555109B2 (en) 2012-01-20 2017-01-31 University Of Cincinnati Method of inhibiting cell proliferation induced by alternatively spliced tissue factor by administering a monoclonal antibody
US10204181B1 (en) * 2015-07-10 2019-02-12 Omnisent LLC Systems and methods for modeling quantum structure and behavior
US10637583B2 (en) 2015-07-10 2020-04-28 Omnisent, LLC Systems and methods for modeling quantum entanglement and performing quantum communication

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3625214A (en) * 1970-05-18 1971-12-07 Alza Corp Drug-delivery device
US4244946A (en) * 1979-06-11 1981-01-13 The Salk Institute For Biological Studies Water-soluble peptides affecting gonadal function
US4305872A (en) * 1979-10-19 1981-12-15 Kenneth Wingrove Polypeptide derivatives
US4316891A (en) * 1980-06-14 1982-02-23 The Salk Institute For Biological Studies Extended N-terminal somatostatin
US4792525A (en) * 1982-08-04 1988-12-20 La Jolla Cancer Research Foundation Tetrapeptide
US4906474A (en) * 1983-03-22 1990-03-06 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
US4629784A (en) * 1983-08-16 1986-12-16 The University Of Georgia Research Foundation, Inc. Synthesis of cyclopropane amino acids
EP0228458B2 (de) * 1985-07-05 1997-10-22 Whitehead Institute For Biomedical Research Expression von fremdem genetischem material in epithelzellen
US4980286A (en) * 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4789734A (en) * 1985-08-06 1988-12-06 La Jolla Cancer Research Foundation Vitronectin specific cell receptor derived from mammalian mesenchymal tissue
AU610083B2 (en) * 1986-08-18 1991-05-16 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents
AU3651689A (en) 1988-06-17 1989-12-21 Mount Sinai School Of Medicine Of The City University Of New York, The Cloning and expression of human tissue factor
CA1340977C (en) * 1988-11-15 2000-04-25 Monty Krieger Scavenger receptor protein and antibody thereto
US5211947A (en) * 1988-12-16 1993-05-18 Schering Corporation Method for lowering blood cholesterol levels with granulocyte-macrophage colony stimulating factor
JPH03290184A (ja) 1990-04-06 1991-12-19 Chugai Pharmaceut Co Ltd スカベンジャーレセプター産生動物細胞
JP3594318B2 (ja) 1990-08-27 2004-11-24 中外製薬株式会社 抗ヒトスカベンジャーレセプター抗体
US5346991A (en) * 1991-06-13 1994-09-13 Genentech, Inc. Tissue factor mutants useful for the treatment of myocardial infarction and coagulopathic disorders
JPH07501204A (ja) 1991-06-28 1995-02-09 マサチューセッツ インスティテュート オブ テクノロジー 局所的オリゴヌクレオチド療法
AU3814393A (en) 1992-03-23 1993-10-21 University Of North Carolina At Chapel Hill, The Small animal model for studying cholesterol metabolism
US5585479A (en) * 1992-07-24 1996-12-17 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human ELAM-I RNA
US5746223A (en) * 1996-10-11 1998-05-05 Williams; Kevin Jon Method of forcing the reverse transport of cholesterol from a body part to the liver while avoiding harmful disruptions of hepatic cholesterol homeostasis
US6429289B1 (en) 1994-06-23 2002-08-06 Massachusetts Institute Of Technology Class BI and CI scavenger receptors
US5652224A (en) * 1995-02-24 1997-07-29 The Trustees Of The University Of Pennsylvania Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism
US5925333A (en) * 1995-11-15 1999-07-20 Massachusetts Institute Of Technology Methods for modulation of lipid uptake

Also Published As

Publication number Publication date
ATE434404T1 (de) 2009-07-15
US7045350B2 (en) 2006-05-16
EP1429650A2 (de) 2004-06-23
EP1429650A4 (de) 2005-11-23
WO2003020111A2 (en) 2003-03-13
EP1429650B1 (de) 2009-06-24
AU2002361471A1 (en) 2003-03-18
US20030049784A1 (en) 2003-03-13
WO2003020111A3 (en) 2004-01-29

Similar Documents

Publication Publication Date Title
DK1140969T3 (da) Bindevævsvækstfaktorfragmenter og fremgangsmåder og anvendelser deraf
MX9606386A (es) Agentes que afectan la hemostasis trombotica.
ATE459369T1 (de) Verfahren zur behandlung von entzündungen
IL190793A0 (en) A fusion polypeptide comprising a collagen binding domain and an angiogenesis modulating domain
CY1111626T1 (el) ΠΑΡΑΛΛΑΓΕΣ ΠΟΛΥΠΕΠΤΙΔΙΩΝ ΠΑΡΑΓΟΝΤΑ VII ´H VIIa
DE69926729D1 (de) Transgenes kaninchen, dass ein funktionelles menschliches lipoprotein(a) exprimiert
DE60232733D1 (de) Alternativ gesplicter zirkulierender gewebefaktor
NO971341L (no) Promoter for reseptor tyrosinkinase TIE
ATE374618T1 (de) Verwendung von rekombinanten menschlichen uteroglobin zur behandlung von fibrotischen krankheitszuständen
DE60206289D1 (de) Verwendung von bibn4096 in kombination mit anderen migränemitteln zur behandlung von migräne
EA200001124A1 (ru) Способ генной терапии
EA199700241A1 (ru) Новые, определенные по составу смеси ферментов для выделения клеток и лечения ран
DE50205466D1 (de) Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen
DE60042793D1 (de) Inhibitor des hepatozytwachstumsfaktoraktivators und dessen verwendung zur modulation von angiogenese und herzvaskularisierung
WO1999058098A3 (en) HUMAN ANTITHROMBIN IIIs AND METHODS RELATED THERETO
ATE236653T1 (de) Kombination in feste dosiermenge von angiotensin- converting-enzyme-hemmern mit calcium-kanal antagonisten zur behandlung von herz- kreislauferkrankungen
ATE360438T1 (de) Verwendung von inaktives cln2 proenzym zur behandlung von lincl
Lesjak et al. Polypeptide proteinase inhibitor from human articular cartilage
DE50202331D1 (de) Verwendung eines phosphatadsorbers gegen gefässerkrankungen
DE60107516D1 (de) Verwendung von Pregabalin zur Asthma Behandlung
DE59805246D1 (de) Tissue-faktor zur beeinflussung von gefässbildung
DE60326161D1 (de) Modifizierte hydrogele und ihre verwendung
UA49753A (uk) Спосіб визначення концентрації захищеного гексапептидного n-кінцевого фрагмента аргінін-вазопресину у водному розчині
FI990799A0 (fi) Menetelmä vierasainepitoisuuden säätämiseksi kalkkikierrossa
UA31369A (uk) Спосіб покращання кровотоку пілородуоденальної зони

Legal Events

Date Code Title Description
8364 No opposition during term of opposition